Iongate BioSciences offers safety pharmacology assays.

If you

• Have developed new molecules against validated targets
• Have completed lead identification / drug candidate nomination
• Have collected a series of compounds with high potency / affinity to your target
• Want to move the best candidate into pre-clinical research
then you may wish to decide which of your compounds has the highest chance of success.

This decision is primarily based on

• Potential side effects with relevance to the future drug approval
• Acceptance of your data by health authorities

It may thus be useful to obtain safety pharmacology data early on.

QT-interval prolongation is one of the most serious side effects of drugs and has been related to several marketing authorization withdrawals of already approved drugs in Europe and North America. The most common mechanism of QT-interval prolongation is the inhibition of potassium channels encoded by a family of genes known under the name hERG.
The International Committee on Harmonization (ICH) has issued a guideline outlining the principles for testing QT-interval prolongation using currents generated by hERG channels as surrogate marker (ICH-S7B).

The company IonGate has developed a cheap and quick solution to generate data on this important safety issue for small and medium sized biotech companies. This includes the hERG channel and other relevant ones. It will allow you a test protocol for hERG potassium channel activity in compliance with ICH and according to GLP.

Please contact us for more information: Dr. Georg Wischnath, phone: +49-5241-4031648, e-mail: GW@vr-p.com.